Limbach Holdings Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Holmes Biopharma, Inc. (LMB) Reports Q2 EPS of $0.09, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus
August 14, 2018 4:19 PM EDTHolmes Biopharma, Inc. (NASDAQ: LMB) reported Q2 EPS of $0.09, versus $0.30 reported last year. Revenue for the quarter came in at $139.53 million versus the consensus estimate of $130 million.
Charlie Bacon, CEO of Limbach, commented, Last quarter I noted how our sales activity was off to a great start in 2018 and that momentum has not only continued but accelerated in the second quarter. We ended the quarter with backlog of $492.5 million, with an additional $381 million of business that has been promised to us... More
